Factors that influence adherence with disease-modifying therapy in MS
- 896 Downloads
The complexity and cost of injection treatment can represent a formidable challenge for patients affected by a chronic illness, particularly those whose treatment is primarily preventative and only modestly effective on the more conspicuous symptomatic aspects of the disease process. The aim of this investigation was to identify which factors most influenced nonadherent behavior with the available diseasemodifying injection therapies for multiple sclerosis (MS).
A multicenter, observational (threewave) study using surveys was developed and administered to patients with MS through the World Wide Web. Healthcare providers at 17 neurology clinics recruited patients for the study.
A total of 798 patients responded to the baseline wave of the study (708 responded to all three waves). The nonadherence rates for all patients (missing one or more injections) across these waves remained relatively stable at 39 %, 37 %, and 36 %, respectively. The most common reason participants listed for missing injections was that they simply forgot to administer the medication (58 %). Other factors including injection-site reactions, quality of life, patients’ perceptions on the injectable medications, hope, depression, and support were also assessed in relation to adherence.
This study characterizes factors that are associated with failure to fully adhere with disease modifying injection therapy for MS and underscores the principles associated with optimizing adherence and its implications for effective treatment of the disease process in MS.
Key wordscompliance adherence multiple sclerosis disease modifying therapy injections
- 1.Beck A, Steer R, Ball R, Ciervo C, Kabat M (1997b) Use of the Beck Anxiety and Depression Inventories for Primary Care with medical outpatients. Assessments 4:211–219Google Scholar
- 4.Bulloch AG, Adair CE, Patten SB (2006) Forgetfulness: a role in noncompliance with antidepressant treatment. Can J Psychiatry — Revue Canadienne de Psychiatrie 51:719–722Google Scholar
- 5.Cohen B (2006) Adherence to diseasemodifying therapy for multiple sclerosis. Int J MS Care 8:32–37Google Scholar
- 6.Devonshire V, Lapierre Y, MacDonell R, Ramo Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Kieseier B, Frohman E, Group obotGS (2006) The Global Adherence Project — A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. In: European Committee for Treatment and Research in Multiple Sclerosis. Madrid, SpainGoogle Scholar
- 7.Fraser C, Hadjimichael O, Vollmer T (2003) Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nursing 35:163–170Google Scholar
- 9.Garcia-Gonzalez A, Richardson M, Popa-Lisseanu MG, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor M (2008) Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 27(7):883–889 (Epub 2008 Jan 8)CrossRefPubMedGoogle Scholar
- 10.Group TIMSS (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661Google Scholar
- 13.Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS, Copolymer 1 Multiple Sclerosis Study G (2001) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology 57:S16–S24PubMedGoogle Scholar
- 19.Sabate E (2003) Adherence to Long-Term therapies — Evidence for Action. World Health Organization, Geneva SwitzerlandGoogle Scholar
- 21.The National Clinical Advisory Board of the National Multiple Sclerosis Society (2008) Assessment Management of Cognitive Impairment in MS. www.nationalmssociety.org. Exput Opinion PapusGoogle Scholar